MONT-SAINT-GUIBERT, Belgium, March 24, 2023 Celyad Oncology , a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies, is pleased to announce. | March 24, 2023
Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD): Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the "Company"), with important changes and
01.03.2023 - Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD): Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the “Company”), with important changes and turning points. Whilst our clinical programs had clear . Seite 1
MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology , with important changes. | February 28, 2023